Vericel Corp Ord (VCEL) is a Healthcare · Biotechnology company listed on NASDAQ. Price $40.02 (-0.03%), Market cap $1.69B, P/E ratio 76.81, 52-week low–high $29.34 ~ $45.70.
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar rem
Financial statements, price targets, institutional (13F) holdings and related news for Vericel Corp Ord are updated in real time on BlackAll Trade.
Vericel Corp Ord trades at $40.02 (-0.03%). Real-time quotes and charts are available on BlackAll Trade.
Vericel Corp Ord has a market cap of about $1.69B. Its P/E ratio is 76.81.
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports